XM Therapeutics
XM Therapeutics, founded in 2022 and based in Providence, Rhode Island, is a life sciences company developing novel therapies to repair and modulate the extracellular matrix (ECM) to treat chronic diseases. Their platform technology generates injectable, acellular designer ECM particles sourced from human 3D cell cultures, targeting chronic heart failure and pulmonary fibrosis initially. The company leverages advanced proteomic profiling and AI to understand and intervene in ECM dysfunction, aiming to improve tissue function and organ repair. XM Therapeutics benefits from close ties to Brown University, with a leadership team of recognized medical experts and experienced MedTech entrepreneurs. Their approach addresses significant unmet clinical needs in cardiovascular and pulmonary diseases, with a large and growing market, positioning them as a pioneering player in ECM-based regenerative medicine.
XM Therapeutics
XM Therapeutics, founded in 2022 and based in Providence, Rhode Island, is a life sciences company developing novel therapies to repair and modulate the extracellular matrix (ECM) to treat chronic diseases. Their platform technology generates injectable, acellular designer ECM particles sourced from human 3D cell cultures, targeting chronic heart failure and pulmonary fibrosis initially. The company leverages advanced proteomic profiling and AI to understand and intervene in ECM dysfunction, aiming to improve tissue function and organ repair. XM Therapeutics benefits from close ties to Brown University, with a leadership team of recognized medical experts and experienced MedTech entrepreneurs. Their approach addresses significant unmet clinical needs in cardiovascular and pulmonary diseases, with a large and growing market, positioning them as a pioneering player in ECM-based regenerative medicine.